Replies to post #142787 on Biotech Values

[jq1234]

GSK will present dabrafenib monotherapy in ph3 melanoma result at ASCO as well. Would be interesting to see efficacy relative to Zelboraf. If I remember correctly the earlier efficacy result wasn't as striking as Zelboraf.

http://abstract.asco.org/AbstView_114_96291.html

GSK combo maybe will show how two average TKIs combined together can produce more dramatic result than each on its own. Hopefully there will be more and more TKIs combination trials in the future.